Wall Street expects CoreWeave stock to jump more than 55% over the coming 12 months, making now, right before 2026, a good ...

The biotech's investigational weight loss drug did very well in a clinical trial. This is a white-hot segment of the pharmaceutical market, so it's little wonder investors subsequently pounced on the ...

Quebecor (TSX:QBR.B) has gone parabolic (≈+62% YTD) but still looks like an attractive mid‑cap growth/dividend‑growth pick ...

Growth stocks are still on the menu for 2026. The first few months of 2025 were a roller-coaster ride that threatened to ...